The Brothers RAF  by Kwong, Lawrence N. & Chin, Lynda
180 Cell 140, January 22, 2010 ©2010 Elsevier Inc.
tion, recent studies have linked DNA 
damage and mitotic spindle check-
points, previously regarded, at least out-
side yeast, as relatively distinct signaling 
pathways (Choi and Lee, 2008; Musaro 
et al., 2008). The study by Royou et al. 
provides a peek into the repair kit for 
mitotic chromosomes. In it we find some 
familiar tools, adapted for unexpected 
applications. Delving further to charac-
terize the complete toolkit will undoubt-
edly reveal additional surprises.
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Comprehensive multidimensional analy-
sis of cancer genomes has revealed a 
staggering level of complexity and vari-
ability even within tumors of the same 
histopathological subtype. These data 
highlight the breadth and depth of the 
constellation of genomic alterations in 
cancer. Although canonical signaling 
pathways seem to be universally deregu-
lated in cancer (Cancer Genome Atlas 
Research Network, 2008), different com-
ponents of a pathway can be altered in 
different tumors. This variability affects 
tumor responses to targeted therapies 
and could explain the limited activity 
observed clinically when targeted thera-
pies are deployed across a group of can-
cer patients with the same histopatho-
logical subtype of tumor. Hence, great 
effort is being devoted to designing and 
developing therapeutic regimens tailored 
to patients whose tumors carry particular 
molecular features. A marquee example 
is the drug trastuzumab, used for treating 
breast cancer. Patients with breast tumors 
harboring amplification or overexpression 
of the HER2/NEU gene, the target of tras-
tuzumab, are more likely to show a clini-
cal response than patients with tumors 
that do not (Smith et al., 2007). But not 
all patients with such signature mutations 
show clinical benefit. One study reported 
that only six out of 100 breast cancer 
patients whose tumors carried HER2 
amplification or overexpression derived 
survival benefits from trastuzumab treat-
ment (Smith et al., 2007). Therefore, 
understanding what dictates responsive-
ness to therapy in the clinic is one of the 
greatest challenges the oncology com-
munity faces, with significant medical and 
economic implications.
Now Heidorn et al. (2010), reporting in 
this issue, identify a new mechanism that 
underlies differential biochemical respon-
siveness to a targeted cancer therapy. 
They show, in melanoma, that drugs that 
specifically inhibit the oncogene BRAF are 
effective in the subpopulation of melano-
mas (?45%) harboring BRAF mutations. 
However, of concern, they discovered 
that these drugs also unleash cancer-
promoting effects in melanomas that har-
bor mutations in the RAS oncogene.
These findings may come as a sur-
prise, as the signaling proteins RAS and 
RAF are depicted as components of the 
same pathway, and RAF is in fact con-
sidered to be an immediate downstream 
signaling surrogate for RAS in the lin-
ear ERK activation cascade. That said, 
groundwork hinting at the complex inter-
play between RAS and RAF has been 
laid by studies on the role of CRAF in 
melanoma. RAS proteins (NRAS, KRAS, 
and HRAS) directly activate RAF pro-
teins (ARAF, BRAF, and CRAF) as part 
of the oncogenic RAS-RAF-MEK-ERK 
signal transduction cascade. The key 
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Targeted molecular therapies for cancer treatment have shown promise, but also have limita-
tions. In this issue, Heidorn et al. (2010) find that a class of targeted molecular therapies 
with clinical effectiveness against one melanoma subtype may have adverse clinical effects in 
another.
Cell 140, January 22, 2010 ©2010 Elsevier Inc. 181
output of this pathway is the phospho-
rylation of the oncogenic kinase ERK to 
pERK, its active form. Thus, activation of 
any upstream element will result in ERK 
phosphorylation. Indeed, overexpres-
sion of RAS, RAF, or MEK isoforms (with 
the possible exception of ARAF) potently 
activates ERK. In melanoma, the majority 
of tumor cells with BRAF mutations har-
bor the V600E mutation, and activation 
of the signaling cascade is presumed 
to be mediated by deregulated BRAF 
(Figure 1A). In contrast, in melanoma 
cells with NRAS mutations, overactive 
NRAS signals through CRAF to activate 
downstream MEK (Figure 1B) (Dumaz et 
al., 2006). This latter result underlies the 
drug responses observed by Heidorn et 
al. (2010) when they targeted the redun-
dant yet intricately interacting RAF pro-
teins in melanoma cells.
Armed with two specific BRAF inhibi-
tors, PLX4720 and 885-A, the authors 
found that ERK phosphorylation was sup-
pressed as expected in BRAF mutant 
melanoma cell lines (Figure 1C), but, sur-
prisingly, was induced in RAS mutant mela-
noma cell lines (Figure 1D). To delineate the 
underlying mechanism of this paradoxical 
response, the authors then used either the 
MEK inhibitor PD184352 or the pan-RAF-
inhibitor sorafenib to show that these com-
pounds can block ERK phosphorylation in 
both BRAF mutant and NRAS mutant cell 
lines. The efficacy of PD184352 in both 
BRAF and NRAS mutant tumor cells sug-
gests that the mechanism lies upstream 
of MEK, whereas the efficacy of sorafenib 
points to CRAF as a critical node. Notably, 
the authors show that the specific BRAF 
inhibitors induce physical binding of BRAF 
to CRAF, upon which BRAF can serve as 
an activating scaffold to enhance CRAF 
signaling to ERK. The authors use an array 
of different BRAF and CRAF mutants to 
dissect the underlying mechanisms: (1) 
non-RAS binding CRAFR89L and BRA-
FR188L mutant proteins demonstrate that 
physical interactions of RAF proteins with 
RAS are required to mediate the signal, 
(2) “gatekeeper threonine” BRAFT529N and 
CRAFT421N mutants that are drug resis-
tant show that binding of a specific BRAF 
inhibitor to BRAF (and hence inhibition of 
BRAF activity) is required for CRAF acti-
vation and that concomitant inhibition of 
CRAF by pan-RAF inhibitors explains their 
suppression of ERK phosphorylation, and 
(3) kinase-dead BRAFD594A or BRAFD594V 
mutants mimic the effect and biochem-
istry of drug-mediated inhibition of BRAF 
with the V600E mutation. These findings 
are further supported by the demonstra-
tion that in a genetically engineered mouse 
model, targeted expression of mutant 
KRAS in melanocytes with wild-type 
BRAF produces only hyperpigmentation 
but when combined with expression of a 
kinase-dead BRAF (which may mimic the 
effects of specific BRAF inhibitors) results 
in malignant melanoma.
This study and other work illuminates 
an intriguing and clinically relevant aspect 
of the dynamic interplay between BRAF 
and CRAF and emphasizes the impor-
tance of genetic context in dictating how 
these interactions impact biological phe-
notypes. BRAFV600E-mediated ERK acti-
vation is enhanced by the genetic inhibi-
tion of CRAF or by blocking the binding 
of active CRAF to BRAF; conversely, this 
ERK activation is suppressed by CRAF 
overexpression (Karreth et al., 2009). 
Other work shows that when oncogenic 
BRAF is inhibited, an increase in CRAF 
levels can sometimes enable melanoma 
cells to acquire drug resistance (Montagut 
et al., 2008). Additionally, use of short hair-
pin RNAs to inhibit both BRAF and CRAF 
in NRAS mutant melanoma xenografts 
potently suppresses tumor growth in vivo, 
whereas inhibition of RAF alone does not. 
This recapitulates the differential effects 
of specific BRAF versus pan-RAF drug 
inhibitors (Jaiswal et al., 2009). Notably, 
however, when CRAF is knocked down 
in these xenografts, ERK phosphorylation 
is virtually extinguished despite contin-
ued tumor growth, suggesting that BRAF 
may exhibit ERK-independent oncogenic 
activity. Finally, in melanoma cells har-
boring the low-activity BRAF mutations, 
D594G or G469E, inhibition of CRAF with 
either sorafenib or small interfering RNAs 
decreases ERK phosphorylation and 
induces apoptosis (Smalley et al., 2009).
Collectively, these studies highlight how 
the two RAFs interact in vivo. First, there 
are clear dissimilarities between BRAF 
and CRAF. When CRAF is inhibited in 
BRAFV600E cells, CRAF’s inhibition of BRAF 
is lifted; when BRAF is inhibited in NRAS 
figure 1. RAf, eRK Phosphorylation, and Melanoma
Inhibition of RAF isoforms produces differential effects on ERK phosphorylation (pERK) depending on the 
melanoma subtype. Most melanomas carrying mutations in BRAF activate the RAS-RAF-MEK-ERK sig-
naling pathway through BRAFV600E, resulting in phosphorylation of ERK (A). However, melanomas carrying 
mutations in NRAS activate signaling through CRAF (B). Inhibition of BRAF in BRAF mutant melanoma 
cells suppresses phosphorylation of ERK, and hence tumor growth (C). However, inhibition of BRAF in 
NRAS mutant cells enhances ERK phosphorylation by inducing BRAF to bind to and activate CRAF (D). 
Dashed lines indicate weak to no signaling.
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mutant cells, it binds to and positively 
activates CRAF (Figure 1D). Whether this 
depends on inherent differences between 
BRAF and CRAF or on the V600E mutation 
in BRAF remains to be determined. Sec-
ond, dual inhibition of RAF may be a valid 
therapeutic approach either alone or in 
combination with MEK inhibition, if CRAF 
is responsible for acquired drug resistance. 
However, existing pan-RAF inhibitors such 
as sorafenib suffer from either nonspecific 
kinase targeting or weak in vivo activity. 
Thus, new second-generation pan-RAF 
inhibitors need to be developed. Finally, 
BRAF and CRAF exemplify the complex-
ity of functionally redundant proteins: their 
effects on one another, including but not 
limited to direct binding, belie any straight-
forward interpretation. This RAF story will 
inform the study of other families of pro-
teins whose redundant nature may be 
deeper than it seems.
The Heidorn et al. study also provides 
a cautionary tale for those enamored 
with the linear pathways presented in 
textbooks, particularly when it comes to 
designing or developing targeted therapy 
clinical trials in cancer. The nonlinear com-
plex interplay between RAS and RAF pro-
teins described here is likely to be the norm 
rather than the exception. As drug design 
continues to focus on molecular targeting 
(e.g., herceptin, sorafenib, and imatinib), 
the nuances of a target’s biological activ-
ity in specific cellular and genetic con-
texts will be crucial for predicting patient 
responses to the drug and potential toxic-
ity. The full molecular effects of a single 
or even a multiple-target regimen must be 
thoroughly explored in a preclinical setting 
prior to, as well as alongside, clinical trials. 
Genome-wide unbiased analyses such as 
genomic, transcriptomic, and proteomic 
profiling will be necessary to identify 
unanticipated points of weakness as well 
as paths to drug resistance (Stommel et 
al., 2007) (Linardou et al., 2008). Heidorn 
and colleagues demonstrate that molecu-
lar analyses of established tumor cell lines 
reveal the potential risk of a promising 
drug type, the specific BRAF inhibitors, 
if used in unselected melanoma patient 
populations.
For personalized medicine to be real-
ized, we need not only a complete atlas 
of genomic events in cancers and how 
such events functionally interact, but also 
an understanding of how such dynamic 
networks respond to genetic and chemi-
cal interference in both preclinical and 
clinical settings. Such mechanistic 
insights into the biology of therapeutic 
targets and the drugs developed against 
them requires a seamless integration of 
basic, translational, and clinical efforts in 
cancer drug development.
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